-
2
-
-
0141799967
-
Changes in the 2003 American Joint Committee on Cancer staging for breast cancer dramatically affect stage-specific survival
-
Woodward W.A., Strom E.A., Tucker S.L., et al. Changes in the 2003 American Joint Committee on Cancer staging for breast cancer dramatically affect stage-specific survival. J Clin Oncol 2003, 21:3244-3248.
-
(2003)
J Clin Oncol
, vol.21
, pp. 3244-3248
-
-
Woodward, W.A.1
Strom, E.A.2
Tucker, S.L.3
-
3
-
-
22244446421
-
The natural history of breast carcinoma in patients with > or = 10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy: a multiinstitutional retrospective study
-
Montero A.J., Rouzier R., Lluch A., et al. The natural history of breast carcinoma in patients with > or = 10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy: a multiinstitutional retrospective study. Cancer 2005, 104:229-235.
-
(2005)
Cancer
, vol.104
, pp. 229-235
-
-
Montero, A.J.1
Rouzier, R.2
Lluch, A.3
-
5
-
-
78649359184
-
Inflammatory breast cancer: the disease, the biology, the treatment
-
Robertson F.M., Bondy M., Yang W., et al. Inflammatory breast cancer: the disease, the biology, the treatment. CA Cancer J Clin 2010, 60:351-375.
-
(2010)
CA Cancer J Clin
, vol.60
, pp. 351-375
-
-
Robertson, F.M.1
Bondy, M.2
Yang, W.3
-
6
-
-
0027191820
-
High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer
-
Peters W.P., Ross M., Vredenburgh J.J., et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993, 11:1132-1143.
-
(1993)
J Clin Oncol
, vol.11
, pp. 1132-1143
-
-
Peters, W.P.1
Ross, M.2
Vredenburgh, J.J.3
-
7
-
-
0030979431
-
High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America
-
Antman K.H., Rowlings P.A., Vaughan W.P., et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 1997, 15:1870-1879.
-
(1997)
J Clin Oncol
, vol.15
, pp. 1870-1879
-
-
Antman, K.H.1
Rowlings, P.A.2
Vaughan, W.P.3
-
8
-
-
0031004064
-
Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results
-
Gianni A.M., Siena S., Bregni M., et al. Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results. J Clin Oncol 1997, 15:2312-2321.
-
(1997)
J Clin Oncol
, vol.15
, pp. 2312-2321
-
-
Gianni, A.M.1
Siena, S.2
Bregni, M.3
-
9
-
-
0030838930
-
High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: prognostic indicators of progression-free and overall survival
-
Somlo G., Doroshow J.H., Forman S.J., et al. High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: prognostic indicators of progression-free and overall survival. J Clin Oncol 1997, 15:2882-2893.
-
(1997)
J Clin Oncol
, vol.15
, pp. 2882-2893
-
-
Somlo, G.1
Doroshow, J.H.2
Forman, S.J.3
-
10
-
-
1842299856
-
Results of a pilot study of 40 patients using high-dose therapy with hematopoietic rescue after standard-dose adjuvant therapy for high-risk breast cancer
-
Tomas J.F., Perez-Carrion R., Escudero A., et al. Results of a pilot study of 40 patients using high-dose therapy with hematopoietic rescue after standard-dose adjuvant therapy for high-risk breast cancer. Bone Marrow Transplant 1997, 19:331-336.
-
(1997)
Bone Marrow Transplant
, vol.19
, pp. 331-336
-
-
Tomas, J.F.1
Perez-Carrion, R.2
Escudero, A.3
-
11
-
-
18544372311
-
Predictors of long-term outcome following high-dose chemotherapy in high-risk primary breast cancer
-
Somlo G., Simpson J.F., Frankel P., et al. Predictors of long-term outcome following high-dose chemotherapy in high-risk primary breast cancer. Br J Cancer 2002, 87:281-288.
-
(2002)
Br J Cancer
, vol.87
, pp. 281-288
-
-
Somlo, G.1
Simpson, J.F.2
Frankel, P.3
-
12
-
-
3042697186
-
Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy
-
Somlo G., Frankel P., Chow W., et al. Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy. J Clin Oncol 2004, 22:1839-1848.
-
(2004)
J Clin Oncol
, vol.22
, pp. 1839-1848
-
-
Somlo, G.1
Frankel, P.2
Chow, W.3
-
13
-
-
0343632389
-
Patient selection in high-dose chemotherapy trials: relevance in high-risk breast cancer
-
Garcia-Carbonero R., Hidalgo M., Paz-Ares L., et al. Patient selection in high-dose chemotherapy trials: relevance in high-risk breast cancer. J Clin Oncol 1997, 15:3178-3184.
-
(1997)
J Clin Oncol
, vol.15
, pp. 3178-3184
-
-
Garcia-Carbonero, R.1
Hidalgo, M.2
Paz-Ares, L.3
-
14
-
-
32944460893
-
High-dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with early poor prognosis breast cancer
-
Farquhar C., Marjoribanks J., Basser R., et al. High-dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with early poor prognosis breast cancer. Cochrane Database Syst Rev 2005, 20:CD003139.
-
(2005)
Cochrane Database Syst Rev
, vol.20
-
-
Farquhar, C.1
Marjoribanks, J.2
Basser, R.3
-
15
-
-
0037445132
-
Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer
-
Henderson I.C., Berry D.A., Demetri G.D., et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003, 21:976-983.
-
(2003)
J Clin Oncol
, vol.21
, pp. 976-983
-
-
Henderson, I.C.1
Berry, D.A.2
Demetri, G.D.3
-
16
-
-
17844403235
-
High-dose paclitaxel in combination with doxorubicin, cyclophosphamide and peripheral blood progenitor cell rescue in patients with high-risk primary and responding metastatic breast carcinoma: toxicity profile, relationship to paclitaxel pharmacokinetics and short-term outcome
-
Somlo G., Doroshow J.H., Synold T., et al. High-dose paclitaxel in combination with doxorubicin, cyclophosphamide and peripheral blood progenitor cell rescue in patients with high-risk primary and responding metastatic breast carcinoma: toxicity profile, relationship to paclitaxel pharmacokinetics and short-term outcome. Br J Cancer 2001, 84:1591-1598.
-
(2001)
Br J Cancer
, vol.84
, pp. 1591-1598
-
-
Somlo, G.1
Doroshow, J.H.2
Synold, T.3
-
17
-
-
0026558969
-
A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy
-
Antman K., Ayash L., Elias A., et al. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 1992, 10:102-110.
-
(1992)
J Clin Oncol
, vol.10
, pp. 102-110
-
-
Antman, K.1
Ayash, L.2
Elias, A.3
-
18
-
-
0035999677
-
The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: an analysis of sequential phase I/II trials from the Dana-Farber/Beth Israel STAMP program
-
Elias A.D., Ibrahim J., Richardson P., et al. The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: an analysis of sequential phase I/II trials from the Dana-Farber/Beth Israel STAMP program. Biol Blood Marrow Transplant 2002, 8:198-205.
-
(2002)
Biol Blood Marrow Transplant
, vol.8
, pp. 198-205
-
-
Elias, A.D.1
Ibrahim, J.2
Richardson, P.3
-
19
-
-
0031036885
-
+ selection and various schedules of stem cell reinfusion and granulocyte colony-stimulating factor priming on hematopoietic recovery after high-dose chemotherapy for breast cancer
-
+ selection and various schedules of stem cell reinfusion and granulocyte colony-stimulating factor priming on hematopoietic recovery after high-dose chemotherapy for breast cancer. Blood 1997, 89:1521-1528.
-
(1997)
Blood
, vol.89
, pp. 1521-1528
-
-
Somlo, G.1
Sniecinski, I.2
Odom-Maryon, T.3
-
20
-
-
0034950262
-
Tandem-cycle high-dose melphalan and cisplatin with peripheral blood progenitor cell support in patients with breast cancer and other malignancies
-
Somlo G., Chow W., Hamasaki V., et al. Tandem-cycle high-dose melphalan and cisplatin with peripheral blood progenitor cell support in patients with breast cancer and other malignancies. Biol Blood Marrow Transplant 2001, 7:284-293.
-
(2001)
Biol Blood Marrow Transplant
, vol.7
, pp. 284-293
-
-
Somlo, G.1
Chow, W.2
Hamasaki, V.3
-
21
-
-
62349125979
-
High-dose chemotherapy for high-risk primary and metastatic breast cancer: is another look warranted?
-
Nieto Y., Shpall E.J. High-dose chemotherapy for high-risk primary and metastatic breast cancer: is another look warranted?. Curr Opin Oncol 2009, 21:150-157.
-
(2009)
Curr Opin Oncol
, vol.21
, pp. 150-157
-
-
Nieto, Y.1
Shpall, E.J.2
-
22
-
-
33644840156
-
Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95
-
Basser R.L., O'Neill A., Martinelli G., et al. Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95. J Clin Oncol 2006, 24:370-378.
-
(2006)
J Clin Oncol
, vol.24
, pp. 370-378
-
-
Basser, R.L.1
O'Neill, A.2
Martinelli, G.3
-
23
-
-
20044364546
-
High-dose chemotherapy and autologous stem cell transplantation as adjuvant therapy for primary breast cancer patients with four or more lymph nodes involved: long-term results of an international randomised trial
-
Coombes R.C., Howell A., Emson M., et al. High-dose chemotherapy and autologous stem cell transplantation as adjuvant therapy for primary breast cancer patients with four or more lymph nodes involved: long-term results of an international randomised trial. Ann Oncol 2005, 16:726-734.
-
(2005)
Ann Oncol
, vol.16
, pp. 726-734
-
-
Coombes, R.C.1
Howell, A.2
Emson, M.3
-
24
-
-
33646863006
-
Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years
-
Hanrahan E.O., Broglio K., Frye D., et al. Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years. Cancer 2006, 106:2327-2336.
-
(2006)
Cancer
, vol.106
, pp. 2327-2336
-
-
Hanrahan, E.O.1
Broglio, K.2
Frye, D.3
-
25
-
-
3242698790
-
Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial
-
Leonard R.C., Lind M., Twelves C., et al. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial. J Natl Cancer Inst 2004, 96:1076-1083.
-
(2004)
J Natl Cancer Inst
, vol.96
, pp. 1076-1083
-
-
Leonard, R.C.1
Lind, M.2
Twelves, C.3
-
26
-
-
34249062028
-
Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup Study 9623
-
Moore H.C., Green S.J., Gralow J.R., et al. Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup Study 9623. J Clin Oncol 2007, 25:1677-1682.
-
(2007)
J Clin Oncol
, vol.25
, pp. 1677-1682
-
-
Moore, H.C.1
Green, S.J.2
Gralow, J.R.3
-
27
-
-
28244478884
-
Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial
-
Nitz U.A., Mohrmann S., Fischer J., et al. Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial. Lancet 2005, 366:1935-1944.
-
(2005)
Lancet
, vol.366
, pp. 1935-1944
-
-
Nitz, U.A.1
Mohrmann, S.2
Fischer, J.3
-
28
-
-
20244377544
-
Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13
-
Peters W.P., Rosner G.L., Vredenburgh J.J., et al. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13. J Clin Oncol 2005, 23:2191-2200.
-
(2005)
J Clin Oncol
, vol.23
, pp. 2191-2200
-
-
Peters, W.P.1
Rosner, G.L.2
Vredenburgh, J.J.3
-
29
-
-
33645304009
-
Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer
-
Rodenhuis S., Bontenbal M., van Hoesel Q.G., et al. Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer. Ann Oncol 2006, 17:588-596.
-
(2006)
Ann Oncol
, vol.17
, pp. 588-596
-
-
Rodenhuis, S.1
Bontenbal, M.2
van Hoesel, Q.G.3
-
30
-
-
0035985269
-
Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up
-
Schrama J.G., Faneyte I.F., Schornagel J.H., et al. Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up. Ann Oncol 2002, 13:689-698.
-
(2002)
Ann Oncol
, vol.13
, pp. 689-698
-
-
Schrama, J.G.1
Faneyte, I.F.2
Schornagel, J.H.3
-
31
-
-
36949036941
-
Phase III study to evaluate the use of high-dose chemotherapy as consolidation of treatment for high-risk postoperative breast cancer: Japan Clinical Oncology Group study, JCOG 9208
-
Tokuda Y., Tajima T., Narabayashi M., et al. Phase III study to evaluate the use of high-dose chemotherapy as consolidation of treatment for high-risk postoperative breast cancer: Japan Clinical Oncology Group study, JCOG 9208. Cancer Sci 2008, 99:145-151.
-
(2008)
Cancer Sci
, vol.99
, pp. 145-151
-
-
Tokuda, Y.1
Tajima, T.2
Narabayashi, M.3
-
32
-
-
34047161056
-
Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy
-
Wilking N., Lidbrink E., Wiklund T., et al. Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy. Ann Oncol 2007, 18:694-700.
-
(2007)
Ann Oncol
, vol.18
, pp. 694-700
-
-
Wilking, N.1
Lidbrink, E.2
Wiklund, T.3
-
33
-
-
44849137163
-
Randomized trial of high-dose adjuvant chemotherapy with autologous hematopoietic stem-cell support versus standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: overall survival after 6 years of follow-up
-
Zander A.R., Schmoor C., Kroger N., et al. Randomized trial of high-dose adjuvant chemotherapy with autologous hematopoietic stem-cell support versus standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: overall survival after 6 years of follow-up. Ann Oncol 2008, 19:1082-1089.
-
(2008)
Ann Oncol
, vol.19
, pp. 1082-1089
-
-
Zander, A.R.1
Schmoor, C.2
Kroger, N.3
-
34
-
-
0038374990
-
Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer
-
Tallman M.S., Gray R., Robert N.J., et al. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med 2003, 349:17-26.
-
(2003)
N Engl J Med
, vol.349
, pp. 17-26
-
-
Tallman, M.S.1
Gray, R.2
Robert, N.J.3
-
35
-
-
67649632544
-
Updated 12-year results of a randomized clinical trial comparing standard-dose to high-dose myeloablative chemotherapy in the adjuvant treatment of breast cancer with more than three positive nodes (LN+) [abstract]
-
Gianni A.M., Bonadonna G. Updated 12-year results of a randomized clinical trial comparing standard-dose to high-dose myeloablative chemotherapy in the adjuvant treatment of breast cancer with more than three positive nodes (LN+) [abstract]. J Clin Oncol 2007, 25:549.
-
(2007)
J Clin Oncol
, vol.25
, pp. 549
-
-
Gianni, A.M.1
Bonadonna, G.2
-
36
-
-
0000142490
-
Adjuvant high-dose chemotherapy (HDC) improves early outcome for high-risk (N >7) breast cancer patients: the PEGASE 01 trial [abstract]
-
Roche H.H., Pouillart P., Meyer N., et al. Adjuvant high-dose chemotherapy (HDC) improves early outcome for high-risk (N >7) breast cancer patients: the PEGASE 01 trial [abstract]. Proc Am Soc Clin Oncol 2001, 20:102.
-
(2001)
Proc Am Soc Clin Oncol
, vol.20
, pp. 102
-
-
Roche, H.H.1
Pouillart, P.2
Meyer, N.3
-
37
-
-
34249063695
-
High-dose chemotherapy for poor prognosis breast cancers: systematic review and meta-analysis
-
Farquhar C., Marjoribanks J., Lethaby A., et al. High-dose chemotherapy for poor prognosis breast cancers: systematic review and meta-analysis. Cancer Treat Rev 2007, 33:325-337.
-
(2007)
Cancer Treat Rev
, vol.33
, pp. 325-337
-
-
Farquhar, C.1
Marjoribanks, J.2
Lethaby, A.3
-
38
-
-
80051991350
-
High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials
-
Berry D.A., Ueno N.T., Johnson M.M., et al. High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. J Clin Oncol 2011, 29:3214-3223.
-
(2011)
J Clin Oncol
, vol.29
, pp. 3214-3223
-
-
Berry, D.A.1
Ueno, N.T.2
Johnson, M.M.3
-
39
-
-
43249092223
-
Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of the WSG AM-01 trial
-
Gluz O., Nitz U.A., Harbeck N., et al. Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of the WSG AM-01 trial. Ann Oncol 2008, 19:861-870.
-
(2008)
Ann Oncol
, vol.19
, pp. 861-870
-
-
Gluz, O.1
Nitz, U.A.2
Harbeck, N.3
-
40
-
-
33846525663
-
High-dose chemotherapy for triple-negative breast cancer
-
De Giorgi U., Rosti G., Frassinetti L., et al. High-dose chemotherapy for triple-negative breast cancer. Ann Oncol 2007, 18:202-203.
-
(2007)
Ann Oncol
, vol.18
, pp. 202-203
-
-
De Giorgi, U.1
Rosti, G.2
Frassinetti, L.3
-
41
-
-
41549148282
-
Pegase 03: a prospective randomized phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer
-
Biron P., Durand M., Roche H., et al. Pegase 03: a prospective randomized phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer. Bone Marrow Transplant 2008, 41:555-562.
-
(2008)
Bone Marrow Transplant
, vol.41
, pp. 555-562
-
-
Biron, P.1
Durand, M.2
Roche, H.3
-
42
-
-
37849033195
-
Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16
-
Crump M., Gluck S., Tu D., et al. Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16. J Clin Oncol 2008, 26:37-43.
-
(2008)
J Clin Oncol
, vol.26
, pp. 37-43
-
-
Crump, M.1
Gluck, S.2
Tu, D.3
-
43
-
-
19944401062
-
High-dose chemotherapy with haematopoietic stem cell transplantation for metastatic breast cancer patients: final results of the French multicentric randomised CMA/PEGASE 04 protocol
-
Lotz J.P., Cure H., Janvier M., et al. High-dose chemotherapy with haematopoietic stem cell transplantation for metastatic breast cancer patients: final results of the French multicentric randomised CMA/PEGASE 04 protocol. Eur J Cancer 2005, 41:71-80.
-
(2005)
Eur J Cancer
, vol.41
, pp. 71-80
-
-
Lotz, J.P.1
Cure, H.2
Janvier, M.3
-
44
-
-
14544306959
-
Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial
-
Schmid P., Schippinger W., Nitsch T., et al. Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial. J Clin Oncol 2005, 23:432-440.
-
(2005)
J Clin Oncol
, vol.23
, pp. 432-440
-
-
Schmid, P.1
Schippinger, W.2
Nitsch, T.3
-
45
-
-
0034643512
-
Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer
-
Stadtmauer E.A., O'Neill A., Goldstein L.J., et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. N Engl J Med 2000, 342:1069-1076.
-
(2000)
Philadelphia Bone Marrow Transplant Group. N Engl J Med
, vol.342
, pp. 1069-1076
-
-
Stadtmauer, E.A.1
O'Neill, A.2
Goldstein, L.J.3
-
46
-
-
31344459870
-
Consolidation with high-dose combination alkylating agents with bone marrow transplantation significantly improves disease-free survival in hormone-insensitive metastatic breast cancer in complete remission compared with intensive standard-dose chemotherapy alone
-
Vredenburgh J.J., Coniglio D., Broadwater G., et al. Consolidation with high-dose combination alkylating agents with bone marrow transplantation significantly improves disease-free survival in hormone-insensitive metastatic breast cancer in complete remission compared with intensive standard-dose chemotherapy alone. Biol Blood Marrow Transplant 2006, 12:195-203.
-
(2006)
Biol Blood Marrow Transplant
, vol.12
, pp. 195-203
-
-
Vredenburgh, J.J.1
Coniglio, D.2
Broadwater, G.3
-
47
-
-
33646815689
-
A randomized phase III comparative trial of immediate consolidation with high-dose chemotherapy and autologous peripheral blood progenitor cell support compared to observation with delayed consolidation in women with metastatic breast cancer and only bone metastases following intensive induction chemotherapy
-
Vredenburgh J.J., Madan B., Coniglio D., et al. A randomized phase III comparative trial of immediate consolidation with high-dose chemotherapy and autologous peripheral blood progenitor cell support compared to observation with delayed consolidation in women with metastatic breast cancer and only bone metastases following intensive induction chemotherapy. Bone Marrow Transplant 2006, 37:1009-1015.
-
(2006)
Bone Marrow Transplant
, vol.37
, pp. 1009-1015
-
-
Vredenburgh, J.J.1
Madan, B.2
Coniglio, D.3
-
48
-
-
80052018701
-
High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: overview of six randomized trials
-
Berry D.A., Ueno N.T., Johnson M.M., et al. High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: overview of six randomized trials. J Clin Oncol 2011, 29:3224-3231.
-
(2011)
J Clin Oncol
, vol.29
, pp. 3224-3231
-
-
Berry, D.A.1
Ueno, N.T.2
Johnson, M.M.3
|